RATIONALE: Major depressive episodes are severe mood episodes which occur both in major depressive disorder and bipolar I and II disorder. Major depressive episodes are characterized by debilitating symptoms that often persist and interfere with typical daily functioning. Various treatments exist for major depressive episodes; however, most primary pharmacologic treatments may take weeks to months to provide relief from depressive symptoms. Ketamine is a demonstrated treatment for major depressive episodes, as relief from depressive symptoms can occur rapidly following treatment. OBJECTIVES: Prior meta-analyses have been conducted to analyze the effectiveness of ketamine for the treatment of major depressive episodes, but at the time of this writing, no meta-analysis had been conducted to observe ketamine treatment efficacy beyond 2 weeks. METHODS: The present meta-analysis evaluated the efficacy of ketamine for the treatment of major depressive episodes; observations of depressive episode severity were analyzed at 2, 4, and 6-weeks post-treatment. RESULTS: The present meta-analysis observed large effects at 2 weeks (g = -1.28), 4 weeks, (g = -1.28), and 6 weeks (g = -1.36) post-treatment. CONCLUSIONS: The results from the present meta-analysis indicate that ketamine can be an effective pharmacologic intervention for major depressive episodes, with treatment effects lasting up to 6 weeks post-ketamine administration, which has many positive implications for treatment.
RATIONALE: Major depressive episodes are severe mood episodes which occur both in major depressive disorder and bipolar I and II disorder. Major depressive episodes are characterized by debilitating symptoms that often persist and interfere with typical daily functioning. Various treatments exist for major depressive episodes; however, most primary pharmacologic treatments may take weeks to months to provide relief from depressive symptoms. Ketamine is a demonstrated treatment for major depressive episodes, as relief from depressive symptoms can occur rapidly following treatment. OBJECTIVES: Prior meta-analyses have been conducted to analyze the effectiveness of ketamine for the treatment of major depressive episodes, but at the time of this writing, no meta-analysis had been conducted to observe ketamine treatment efficacy beyond 2 weeks. METHODS: The present meta-analysis evaluated the efficacy of ketamine for the treatment of major depressive episodes; observations of depressive episode severity were analyzed at 2, 4, and 6-weeks post-treatment. RESULTS: The present meta-analysis observed large effects at 2 weeks (g = -1.28), 4 weeks, (g = -1.28), and 6 weeks (g = -1.36) post-treatment. CONCLUSIONS: The results from the present meta-analysis indicate that ketamine can be an effective pharmacologic intervention for major depressive episodes, with treatment effects lasting up to 6 weeks post-ketamine administration, which has many positive implications for treatment.
Entities:
Keywords:
Bipolar; Depression; Ketamine; MDD; Major depressive episodes
Authors: C Sophia Albott; Kelvin O Lim; Miriam K Forbes; Christopher Erbes; Susanna J Tye; John G Grabowski; Paul Thuras; Tegan M Batres-Y-Carr; Joseph Wels; Paulo R Shiroma Journal: J Clin Psychiatry Date: 2018 May/Jun Impact factor: 4.384
Authors: Chadi G Abdallah; Thomas G Adams; Benjamin Kelmendi; Irina Esterlis; Gerard Sanacora; John H Krystal Journal: Depress Anxiety Date: 2016-04-06 Impact factor: 6.505
Authors: Elizabeth D Ballard; Dawn F Ionescu; Jennifer L Vande Voort; Mark J Niciu; Erica M Richards; David A Luckenbaugh; Nancy E Brutsché; Rezvan Ameli; Maura L Furey; Carlos A Zarate Journal: J Psychiatr Res Date: 2014-08-12 Impact factor: 4.791
Authors: Sara Costi; Laili Soleimani; Andrew Glasgow; Jess Brallier; John Spivack; Jaclyn Schwartz; Cara F Levitch; Samantha Richards; Megan Hoch; Elizabeth C Stade; Alison Welch; Katherine A Collins; Adriana Feder; Dan V Iosifescu; Dennis S Charney; James W Murrough Journal: Neuropsychopharmacology Date: 2019-03-11 Impact factor: 8.294
Authors: Miguel Pérez de la Mora; Dasiel O Borroto-Escuela; Minerva Crespo-Ramírez; José Del Carmen Rejón-Orantes; Daniel Alejandro Palacios-Lagunas; Magda K Martínez-Mata; Daniela Sánchez-Luna; Emiliano Tesoro-Cruz; Kjell Fuxe Journal: Cells Date: 2022-06-02 Impact factor: 7.666
Authors: Matti Gärtner; Anne Weigand; Milan Scheidegger; Mick Lehmann; Patrik O Wyss; Andreas Wunder; Anke Henning; Simone Grimm Journal: Eur Arch Psychiatry Clin Neurosci Date: 2022-01-12 Impact factor: 5.760